Anti-SARS Cov-2 T Cell Infusions for COVID 19

SARS-CoV 2 Clinical Trial

— BATIT  

Official title:

BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04401410
• Other study ID #: H-47739 BAT IT
• Status: Terminated
• Phase: Phase 1
• Start date: November 4, 2020
• Est. completion date: October 12, 2021

Study information

• Verified date: December 2022
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation. The SARS-CoVSTs lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. These cell lines were frozen for later use and will be thawed and used to treat patients who meet the eligibility criteria.

Description:

The first part of this study is to identify the maximum tolerated dose (MTD) of allogeneic SARS-CoV2-specific T cells (SARS-CoVSTs) for patients with COVID19 with high risk of progression to mechanical ventilation. The 3 dose levels (DL) are: DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose) Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level. After the dose finding phase is complete and the MTD established, a randomized trial will be conducted. Patient will be randomized 1:1 using the permuted block method with a block size of 4 (2 in the treatment arm and 2 in the control arm) to receive treatment with SARS-CoVSTs or routine treatment per institutional standards. All enrolled patients will undergo the following evaluations: - Physical exam and history including height and weight - SARS-CoV-2 test - Blood tests - Chest X-ray or chest CT Scan if not already done in the past 48 hours. - A urine pregnancy test, when applicable Patients randomized to receive SARS-CoVSTs will be pre-medicated with Benadryl and Tylenol. The cells will be thawed and given through an intravenous line. Patients will be monitored for infusion side effects for up to 14 days or until infusion side effects have completely resolved, whichever is longer. Blood will be drawn before the infusion and then up to daily for 14 days or until the patient is discharged from the hospital. Optional blood samples will be drawn at 2, 3 and 6 months after infusion. Study participation will last 6 months after the date of infusion.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: October 12, 2021
• Est. primary completion date: October 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. SARS-CoV-2 infection confirmed by polymerase chain reaction assay (PCR) from a nasopharyngeal swab or other accepted specimen type. (If testing was performed = 5 days before enrollment, this must be repeated and accept only if positive again). Date of COVID test must be = 5 days prior to infusion.

2. Currently hospitalized adult patient (= 18 years of age) requiring medical care for COVID19

3. Peripheral oxygen saturation (SpO2) = 92% on room air

4. Hgb = 7.0 gm/dl

5. Negative pregnancy test (if applicable)

6. Patient or parent/guardian capable of providing informed consent (may be obtained electronically)

7. Evidence of pulmonary infiltrates on chest imaging. Any chest imaging findings which would be consistent with COVID19 would qualify (Eg: ground glass opacities, multifocal infiltrates etc.)

8. High risk of requiring mechanical ventilation as defined by at least two of the

following:

1. Age = 60 years of age

2. Age = 75 years of age (counts as meeting two criteria)

3. Hypertension (HTN)

4. Chronic cardiovascular disease other than HTN (eg: Coronary artery disease, congestive heart failure or cardiomyopathies).

5. Diabetes Mellitus

6. Obesity (BMI = 30)

7. Obesity (BMI = 40, counts as meeting two criteria)

8. Active cancer diagnosis or ongoing (within 3 months) cytotoxic chemo/ radio-therapy for a cancer

9. Post-hematopoeitic stem cell or solid organ transplantation status

10. Immunodeficiency states including HIV infection on antiretroviral therapy (except those listed as exclusion criteria #1, #7 and #10) as determined by the treating physician (eg: receiving immunosuppressive therapy like rituximab or congenital immunodeficiency syndromes, prior treatment with chemotherapy greater than 3 months ago but per investigators discretion could have lingering effects on the immune system, eg: chemotherapy regimens for lymphomas, ALL or AML etc.)

11. Chronic obstructive pulmonary disease (COPD)

12. Current everyday smoker

13. Chronic kidney disease (eGFR < 30 mL/min/1.73 m2 )

14. Bronchial asthma (on active treatment prior to admission, eg. Use of rescue inhalers or inhaled corticosteroids or other treatments to prevent/treat attacks). Exclusion Criteria

1. Received Anti-thymocyte globulin (ATG), Campath or other T cell immunosuppressive monoclonal antibodies in the 28 days prior to screening for enrollment

2. Requiring mechanical ventilation at time of T cell infusion

3. Alanine aminotransferase or aspartate aminotransferase greater than 5 x upper limit of normal

4. If previously undergone an allogeneic hematopoietic stem cell transplant and have evidence of active acute GVHD greater than or equal to grade 2

5. Uncontrolled relapse of malignancy

6. Requiring vasopressors

7. Known history of autoimmune disease except prior thyroiditis

8. Is not suitable at the discretion of the treating physician

9. Patients on greater than 6mg/day of dexamethasone (IV) or equivalent

10. Greater than grade 1 CRS per American Society for Transplantation and Cellular Therapy (ASTCT) criteria

11. Patients should not be enrolled on any other interventional clinical trials for COVID19. Patients may receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).

Related Conditions & MeSH terms

• COVID 19
• COVID-19
• SARS-CoV 2
• Viral Infection
• Virus Diseases

Intervention

Biological:
• Dose Finding Phase (MTD)
Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
• Partially HLA-matched SARS-CoVSTs
Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase

Other:
• Routine care (no SARS-CoVSTs)
Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).

Locations

Country	Name	City	State
United States	Houston Methodist Hospital	Houston	Texas

Sponsors (4)

Lead Sponsor	Collaborator
Baylor College of Medicine	AlloVir, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Escalation Phase: Rate of Dose Limiting Toxicities by CTCAE 5.0 [14 days post infusion]	Defined as the proportion of subjects with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment. A dose limiting toxicity is defined as any acute GvHD (> grade 2), grade =3 CRS or ICANS, grade =3 hematologic toxicity or grade =3 non-hematologic adverse events related to the T cell product within 14 days of the VST infusion and that are not due to pre-existing conditions as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.	14 days post infusion
Primary	Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge]	Clinical Response rate is defined as the proportion of subjects reporting an increase in 2 or more points on the WHO Ordinal Scale. [Scored on a scale from 0 to 8; where 0 = Uninfected and 8 =Dead] or until patient is discharged.	7 Days post-randomization or at time of hospital discharge
Secondary	Randomized Trial: Rate of Treatment-related adverse events (tAE) by CTCAE 5.0 [14 days post-randomization]	Defined as the proportion of subjects with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment. Treatment-related adverse events (tAE) are defined as any acute GvHD (> grade 2), grade =3 CRS or ICANS, grade =3 hematologic toxicity or grade =3 non-hematologic adverse events related to the T cell product within 14 days of the VST infusion and that are not due to pre-existing conditions as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.	14 days post-randomization